Great Lakes Advisors LLC Acquires 214,375 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Great Lakes Advisors LLC lifted its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 130.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 379,187 shares of the medical technology company's stock after buying an additional 214,375 shares during the period. Great Lakes Advisors LLC owned approximately 0.27% of Alphatec worth $3,481,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Alphatec by 11.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock worth $16,280,000 after buying an additional 297,850 shares during the period. Barclays PLC grew its stake in shares of Alphatec by 362.3% in the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock worth $948,000 after purchasing an additional 133,653 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Alphatec by 299.3% in the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock worth $343,000 after purchasing an additional 48,308 shares during the last quarter. Royce & Associates LP grew its stake in shares of Alphatec by 15.9% in the third quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company's stock worth $6,740,000 after purchasing an additional 165,954 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Alphatec by 10.1% in the third quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock worth $17,453,000 after purchasing an additional 287,350 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, EVP David Sponsel sold 36,256 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $11.42, for a total value of $414,043.52. Following the completion of the transaction, the executive vice president now directly owns 735,074 shares in the company, valued at $8,394,545.08. The trade was a 4.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick Miles sold 6,687 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the completion of the transaction, the chief executive officer now owns 5,501,715 shares of the company's stock, valued at approximately $66,020,580. The trade was a 0.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 337,321 shares of company stock worth $3,828,060 in the last three months. Insiders own 22.80% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on ATEC. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Piper Sandler raised their target price on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Finally, Barclays lifted their price objective on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $17.67.

Alphatec Stock Up 2.1 %

Shares of ATEC stock traded up $0.20 during trading hours on Wednesday, hitting $9.54. 2,161,949 shares of the company's stock traded hands, compared to its average volume of 1,976,446. The stock's fifty day simple moving average is $10.95 and its two-hundred day simple moving average is $8.80. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $14.88. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -7.45 and a beta of 1.39. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business had revenue of $176.79 million for the quarter, compared to analysts' expectations of $172.74 million. On average, analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.